Campbell Rogers, Chief Medical Officer of Heartflow, Inc., filed a Form 4 on October 26, 2026, disclosing option exercises and a sale of common stock executed on October 22, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Sale of 23,933 shares: Rogers sold 23,933 shares of common stock at $55.01 per share on October 22, 2026, according to the filing.
  • Two option exercises: Rogers exercised a stock option for 12,329 shares at $8.33 and a second option for 5,101 shares at $2.22, both on October 22, 2026.
  • 10b5-1 plan: The filing states all transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Rogers on June 16, 2026.
  • Direct ownership after transactions: Rogers held 73,453 shares of common stock directly following the reported transactions.
  • Indirect holdings: Rogers also holds shares indirectly through four trusts: 22,615 shares by the Campbell Rogers 2019 Irrevocable Trust, 46,159 shares by the CR Asset Protection Trust of 2023, 26,012 shares by Spouse's Trust, and 50,754 shares by The Campbell Rogers Revocable Trust.
  • Remaining options: After the exercises, Rogers retained 19,127 stock options at $8.33 and 65,682 stock options at $2.22, held directly.

Rogers Campbell's October 2026 Transactions at Heartflow

According to the Form 4 filed with the SEC, Campbell Rogers, identified as Chief Medical Officer of Heartflow, Inc. (NASDAQ:HTFL), reported three transactions in the company's common stock on October 22, 2026. Two transactions involved the exercise of stock options under transaction code "M," and one involved a sale of common stock under transaction code "S."

The filing discloses that Rogers exercised 12,329 stock options at an exercise price of $8.33 per share and 5,101 stock options at $2.22 per share. The filing notes that the $8.33 options "are fully exercisable," while the $2.22 options "vest and become exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date." Following the exercises, Rogers retained 19,127 options at $8.33 and 65,682 options at $2.22.

The sale of 23,933 shares at $55.01 per share is described in the filing as including "6,503 shares of common stock held and the option exercise and sale of 17,430 shares." All reported transactions were effected pursuant to a Rule 10b5-1 trading plan that Rogers adopted on June 16, 2026. The Form 4 was signed by Nga Van under power of attorney and filed on October 26, 2026.

What Was Disclosed

Heartflow, Inc.'s Chief Medical Officer, Campbell Rogers, disclosed option exercises totaling 17,430 shares and a combined sale of 23,933 shares of common stock on October 22, 2026, all conducted under a pre-established Rule 10b5-1 trading plan adopted June 16, 2026.